Research Papers: Immunology:
NBAT1 suppresses breast cancer metastasis by regulating DKK1 via PRC2
Metrics: PDF 4517 views | HTML 3681 views | ?
Pengnan Hu1,2,3,*, Junjun Chu1,3,*, Yanqing Wu1,3, Lijuan Sun1,3, Xiaobin Lv1,3, Yinghua Zhu1,3, Jingjing Li1,3, Qiannan Guo1,3, Chang Gong1,3, Bodu Liu1,2,3 and Shicheng Su1,3
1 Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
2 Key Laboratory of Gene Engineering of Ministry of Education, State Key Laboratory of Biocontrol, School of Life Sciences, Sun Yat-sen University, China
3 Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
* These authors have contributed equally to this work
Shicheng Su, email:
Bodu Liu, email:
Keywords: LncRNA; NBAT1; breast cancer; metastasis
Received: May 04, 2015 Accepted: August 26, 2015 Published: September 10, 2015
Long noncoding RNA NBAT1 (neuroblastoma associated transcript 1) regulates cell proliferation and invasion by interacting with PRC2 (polycomb repressive complex 2) member EZH2 (enhancer of zeste 2). Decreased expression of NBAT1 is associated with poor clinical outcome in neuroblastomas. However, the roles of NBAT1 in other cancers remain unknown. Here, we report that NBAT1 is down-regulated in various types of cancer. Particularly, reduced NBAT1 in breast cancer is associated with tumor metastasis and poor patient prognosis. In vitro, ectopic NBAT1 inhibits migration and invasion of breast cancer cells. Mechanistic study shows that NBAT1 is associated with PRC2 member EZH2 and regulates global gene expression profile. Among them, DKK1 (dickkopf WNT signaling pathway inhibitor 1) is found to be regulated by NBAT1 in a PRC2 dependent manner, and is responsible for NBAT1’s effects in inhibiting migration and invasion of breast cancer cells. Taken together, our study demonstrates that long noncoding RNA NBAT1 is a potential breast cancer prognostic marker, as well as a potential therapeutic target to inhibit breast cancer metastasis.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.